Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted) (2010 - 2026)
Anika Therapeutics (ANIK) reported EPS (Weighted Average and Diluted) of -$0.37 for Q1 2026, down 8.82% year-over-year from -$0.41 in Q1 2025, and down 716.67% quarter-over-quarter from $0.06 in Q4 2025.
Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.37 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.37, down 8.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.8 (up 58.97% YoY), and the FY2025 annual result was -$0.76, up 80.16% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.37 in Q1 2026 per ANIK's latest filing, from $0.06 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $144.29 in Q2 2024 and troughed at -$1.49 in Q4 2024.
- A 5-year average of $8.23 and a median of -$0.29 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) sank 825.0% in 2022, then jumped 76044.27% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.34 in 2022, then soared by 426.47% to $1.11 in 2023, then tumbled by 234.23% to -$1.49 in 2024, then jumped by 104.03% to $0.06 in 2025, then sank by 716.67% to -$0.37 in 2026.
- Business Quant data shows ANIK's EPS (Weighted Average and Diluted) at -$0.37 in Q1 2026, $0.06 in Q4 2025, and -$0.16 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -0.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.37 |
| Dec 31, 2025 | 0.06 |
| Sep 30, 2025 | -0.16 |
| Jun 30, 2025 | -0.33 |
| Mar 31, 2025 | -0.34 |
| Dec 31, 2024 | -1.49 |
| Sep 30, 2024 | -0.12 |
| Jun 30, 2024 | 144.29 |
| Mar 31, 2024 | -0.31 |
| Dec 31, 2023 | 1.11 |
| Sep 30, 2023 | -0.45 |
| Jun 30, 2023 | -0.19 |
| Mar 31, 2023 | -0.71 |
| Dec 31, 2022 | -0.34 |
| Sep 30, 2022 | -0.29 |
| Jun 30, 2022 | -0.20 |
| Mar 31, 2022 | -0.20 |
| Dec 31, 2021 | -0.40 |
| Sep 30, 2021 | 0.04 |
| Jun 30, 2021 | 0.45 |